Data & Analytics

The Era of DTC Diagnostics, Diagnosis and Drug Development Is Here

The Era of DTC Diagnostics, Diagnosis and Drug Development Is Here

Despite conventional wisdom that the 23andMe business breakthrough is the direct-to-consumer model, it's also the consolidation of genetic testing, diagnosis and drug development that has the potential to change the industry.

Five things for pharma marketers to know: Thursday, December 3, 2015

Five things for pharma marketers to know: Thursday, December 3, 2015

By

Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad

Data Management: Not If, But When

Data Management: Not If, But When

Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage

IMS Health: Drug spend will steadily rise through 2020

IMS Health: Drug spend will steadily rise through 2020

By

Specialty medicines will keep drug spend trending upward through the next five years.

Late-Phase Diabetes Research: Time To Get Onboard

Late-Phase Diabetes Research: Time To Get Onboard

If more physicians begin participating in late-phase research efforts—and work to educate patients about these opportunities—we can expect new innovations in treatment solutions to come more quickly to market.

How IBM's cognitive computing platform might help make healthcare smarter

How IBM's cognitive computing platform might help make healthcare smarter

Soon, IBM says, Watson will be used by one particular pharma company to create a website where, once a drug is prescribed, patients can ask questions in their own words and the website will provide answers in near real-time.

Is pharma's access to physicians decreasing or increasing?

Is pharma's access to physicians decreasing or increasing?

By

A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.

Drugmakers spend too much on marketing: Kaiser poll

Drugmakers spend too much on marketing: Kaiser poll

By

The public said drugmakers spend too much money on marketing to doctors and patients

Pharma's acceptance of transparency programs matures as reporting becomes global

Pharma's acceptance of transparency programs matures as reporting becomes global

By

Initiatives in Europe follow the US example when it comes to requiring manufacturers to report information about financial relationships with physicians.

Five things for pharma marketers to know: Friday, October 23, 2015

Five things for pharma marketers to know: Friday, October 23, 2015

By

Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug

Wearables Create a New World of Data for Clinical R&D

Wearables Create a New World of Data for Clinical R&D

By equipping patients with biosensors, wearable devices and mobile apps, clinical R&D teams have the opportunity to gain unprecedented insight about the patient experience.

Bristol-Myers Squibb extends relationship with ZS

Bristol-Myers Squibb extends relationship with ZS

By

The firm is the primary vendor for the drugmaker's global commercial analytics.

Analysis shows pharma is getting better at R&D

Analysis shows pharma is getting better at R&D

By

An analysis of R&D data from 14 large drugmakers found that pharma is having renewed success in bringing medicines to market.

Five things for pharma marketers to know: Tuesday, September 22, 2015

Five things for pharma marketers to know: Tuesday, September 22, 2015

By

Report finds Americans overpay for cancer drugs; Clinton proposes end to pharma DTC as a tax write-off; Gilead HCV combo is effective across all strains of the virus

Smart devices will improve pharma sales: survey

Smart devices will improve pharma sales: survey

By

Accenture found that life-sciences executives believe that smart tools and devices will be the catalyst for drugmakers to move forward with beyond-the-pill initiatives.

Today the clinical trial, tomorrow the world

Today the clinical trial, tomorrow the world

By

As the value proposition of real-world data to drugmakers becomes increasingly attractive, services companies are partnering to capitalize on the opportunity.

Five things for pharma marketers to know: Thursday, September 10, 2015

Five things for pharma marketers to know: Thursday, September 10, 2015

By

Cardiologists say that up to 15% of their patients could be on PCSK9 inhibitors next year; FDA committee to evaluate new Oxycodone version

Pharma sales forces should act more like 'outcomes advocates'

Pharma sales forces should act more like 'outcomes advocates'

By

Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.

Inovalon scoops up consultancy Avalere Health

Inovalon scoops up consultancy Avalere Health

By

The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.

Poll: Majority of Americans support government negotiation of drug prices

Poll: Majority of Americans support government negotiation of drug prices

By

A new poll conducted by the Kaiser Family Foundation found that most Americans believe drugmakers should be required to release information to the public about how they set drug prices.

Most docs are in the dark about biosimilars: survey

Most docs are in the dark about biosimilars: survey

By

Less than half of 300 doctors polled in a QuantiaMD survey could name a biosimilar that's under consideration for approval, and only 17% said they're very likely to prescribe one.

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.

NORD and University of Maryland partner for rare-disease research training

The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.

Some heartburn drugs linked to increased risk of heart attack

A data-mining analysis of patient records found a significant increase in the chance of heart attack for those taking proton-pump inhibitors.

A Q&A with Rob Rogers, 2015 Lions Health pharma jury president

A Q&A with Rob Rogers, 2015 Lions Health pharma jury president

By

He spoke with MM&M about whether pharma is ready to win a Grand Prix, if regulation limits creativity in healthcare, and why wearables may spur creativity.

Five things for pharma marketers to know: Tuesday, April 14

Five things for pharma marketers to know: Tuesday, April 14

By

IBM takes on healthcare data; Mylan settled a lawsuit allowing it to launch generic Viagra by 2017; an FDA committee will meet today to discuss Onglyza

New guidelines recommend wait-and-see strategy for sinus infections

The American Academy of Otolaryngology said taking antibiotics for sinus infections is a slightly better treatment strategy than waiting it out.

Survey suggests doctors increasingly look for digital engagement

A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.

Better Rx coverage associated with outcomes lift: study

Better Rx coverage associated with outcomes lift: study

By

A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.

Playing to Win in the Global Biosimilars Environment

Playing to Win in the Global Biosimilars Environment

By

"Although the United States represents almost half of the biologics market in terms of revenue and volume, biosimilars growth will be fueled by focusing on the emerging markets, by addressing non-consumption and patient inability to pay for high-priced biologics."

Email Newsletters